T4a期喉癌根治性治疗后的失败模式分析
该回顾性数据库研究纳入2000至2017年退伍军人事务部数据库中1043例T4a期喉鳞状细胞癌患者,比较放化疗与手术(全喉切除+颈清扫+辅助治疗)后的复发模式。手术组局部区域复发和远处复发均低于放化疗组,多因素回归显示手术与更优的局部区域控制、远处复发、总死亡率和喉癌死亡率相关。
要点
- 手术组局部区域复发率23.0%低于放化疗组37.2%,远处复发率6.8%低于13.3%。
- 手术与更优的总死亡率和喉癌死亡率独立相关。
核心结论
- T4a期喉鳞癌手术与放化疗的生存差异受不同复发行为影响,手术与更优的疾病控制和生存相关。
研究设计与样本
- 回顾性数据库综述,基于退伍军人事务部国家数据库,纳入2000至2017年1043例T4a期喉鳞癌患者,其中放化疗组438例,手术组605例。
主要发现
- 放化疗组淋巴结阳性比例高于手术组(64.6% vs 53.1%,P < .001)。
- 手术组局部区域复发率低于放化疗组(23.0% vs 37.2%,P < .001),远处复发率亦较低(6.8% vs 13.3%,P < .001)。
- N0亚组中两组远处转移率无差异(P = .722)。
- 多因素回归显示手术与更优的局部区域复发(HR 0.49;95% CI 0.39-0.62;P < .001)、远处复发(HR 0.47;95% CI 0.31-0.71;P < .001)、总死亡率(HR 0.75;95% CI 0.64-0.87;P < .001)和喉癌死亡率(HR 0.69;95% CI 0.56-0.85;P < .001)相关。
临床怎么用
- 对于T4a期喉鳞癌,手术可能与更好的局部区域控制、远处复发控制和生存相关,决策时需结合区域淋巴结负荷综合评估。
局限性
- 本研究为回顾性数据库综述,可能存在选择偏倚和未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Recurrence is known to predict laryngeal squamous cell cancer (LSCC) survival. Recurrence patterns in T4a LSCC are poorly characterized and represent a possible explanation for observed survival discrepancies by treatment rendered. STUDY DESIGN: Retrospective database review. SETTING: Veterans Affairs national database. METHODS: Patients with T4a LSCC between 2000 and 2017 were identified and stratified by treatment (chemoradiotherapy [CRT] vs total laryngectomy + neck dissection + adjuvant therapy [surgical]). Primary outcomes were locoregional and distant recurrence. Secondary outcomes of overall mortality, larynx cancer mortality, and noncancer mortality were evaluated in Cox and Fine-Gray models. RESULTS: A total of 1043 patients had comparable baseline demographics: 438 in the CRT group and 605 in the surgical group. Patients undergoing CRT had higher proportions of node positivity (64.6% vs 53.1%, P < .001). Locoregional and distant recurrence were less common in the surgical group (23.0% vs 37.2%, P < .001; 6.8% vs 13.3%, P < .001, respectively); however, distant metastatic rates did not differ within the N0 subgroup (P = .722). On multivariable regression, surgery demonstrated favorable locoregional recurrence (hazard ratio [HR], 0.49; 95% CI, 0.39-0.62; P < .001), distant recurrence (HR, 0.47; 95% CI, 0.31-0.71; P < .001), overall mortality (HR, 0.75; 95% CI, 0.64-0.87; P < .001), and larynx cancer mortality (HR, 0.69; 95% CI, 0.56-0.85; P < .001). CONCLUSION: T4a LSCC survival discrepancies between surgical and nonsurgical treatment are influenced by varying recurrence behaviors. Surgery was associated with superior disease control and improved survival. Beyond the known benefit in locoregional control with surgery, there may be a protective effect on distant recurrence that depends on regional disease burden.
引用
- Voora RS, Panuganti BA, Flagg M, et al. Patterns of Failure After Definitive Treatment of T4a Larynx Cancer. Otolaryngol Head Neck Surg. 2021. PMID: 34609937. doi:10.1177/01945998211049211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。